Savara Past Earnings Performance
Past criteria checks 0/6
Savara's earnings have been declining at an average annual rate of -8.3%, while the Biotechs industry saw earnings growing at 17.5% annually. Revenues have been declining at an average rate of 70.8% per year.
Key information
-8.35%
Earnings growth rate
31.67%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | -70.84% |
| Return on equity | -69.11% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
No updates
Recent updates
Savara: Make-It-Or-Break-It Molbreevi BLA Filing
Apr 21Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Apr 03
Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track
Dec 20Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Revenue & Expenses Breakdown
How Savara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 0 | -102 | 29 | 3 |
| 31 Dec 24 | 0 | -96 | 25 | 0 |
| 30 Sep 24 | 0 | -83 | 22 | 33 |
| 30 Jun 24 | 0 | -75 | 20 | 15 |
| 31 Mar 24 | 0 | -64 | 18 | 16 |
| 31 Dec 23 | 0 | -55 | 16 | 0 |
| 30 Sep 23 | 0 | -49 | 14 | 0 |
| 30 Jun 23 | 0 | -43 | 12 | 17 |
| 31 Mar 23 | 0 | -40 | 12 | 0 |
| 31 Dec 22 | 0 | -38 | 11 | 0 |
| 30 Sep 22 | 0 | -39 | 11 | 0 |
| 30 Jun 22 | 0 | -39 | 12 | 0 |
| 31 Mar 22 | 0 | -41 | 12 | 0 |
| 31 Dec 21 | 0 | -43 | 12 | 0 |
| 30 Sep 21 | 0 | -45 | 12 | 0 |
| 30 Jun 21 | 0 | -46 | 12 | 0 |
| 31 Mar 21 | 0 | -44 | 12 | 0 |
| 31 Dec 20 | 0 | -50 | 12 | 0 |
| 30 Sep 20 | 0 | -68 | 12 | -30 |
| 30 Jun 20 | 0 | -69 | 12 | -20 |
| 31 Mar 20 | 0 | -81 | 13 | -10 |
| 31 Dec 19 | 0 | -78 | 13 | 0 |
| 30 Sep 19 | 0 | -57 | 13 | 40 |
| 30 Jun 19 | 0 | -57 | 13 | 40 |
| 31 Mar 19 | 0 | -47 | 11 | 39 |
| 31 Dec 18 | 0 | -62 | 10 | 37 |
| 30 Sep 18 | 0 | -58 | 8 | 34 |
| 30 Jun 18 | 0 | -52 | 9 | 29 |
| 31 Mar 18 | 0 | -53 | 7 | 24 |
| 31 Dec 17 | 0 | -31 | 7 | 19 |
| 30 Sep 17 | 0 | -28 | 7 | 16 |
| 30 Jun 17 | 0 | -25 | 4 | 13 |
| 31 Mar 17 | 0 | -14 | 4 | 10 |
| 31 Dec 16 | 0 | -11 | 3 | 8 |
| 31 Dec 15 | 0 | -9 | 2 | 4 |
| 31 Dec 14 | 2 | -6 | 2 | 5 |
Quality Earnings: SVRA is currently unprofitable.
Growing Profit Margin: SVRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SVRA is unprofitable, and losses have increased over the past 5 years at a rate of 8.3% per year.
Accelerating Growth: Unable to compare SVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: SVRA has a negative Return on Equity (-69.11%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 13:08 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Savara Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Jonathan Wolleben | Citizens JMP Securities, LLC |